Literature DB >> 15854256

Pituitary carcinoma: a clinicopathological review.

Bernd W Scheithauer1, Ozlem Kurtkaya-Yapicier, Kalman T Kovacs, William F Young, Ricardo V Lloyd.   

Abstract

Pituitary carcinomas are rare tumors; less than 100 well-documented cases have been reported to date. Such tumors are aggressive and associated with a high mortality rate. The molecular events leading to the development of pituitary carcinomas are largely unknown. Recent studies have only begun to shed light on the probable mechanisms of tumor initiation and progression. A review of the clinicopathological and molecular genetic characteristics of pituitary carcinomas is presented.

Entities:  

Mesh:

Year:  2005        PMID: 15854256

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  41 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 2.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

3.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

4.  Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.

Authors:  Yoshikazu Ogawa; Mika Watanabe; Teiji Tominaga
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

5.  Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Long Jin; Gail A Stilling; Heyu Zhang; Xiang Qian; Nobuki Nakamura; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

6.  Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.

Authors:  George Vlotides; Emily Siegel; Ines Donangelo; Shiri Gutman; Song-Guang Ren; Shlomo Melmed
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 7.  Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Authors:  Frederick Yoo; Edward C Kuan; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 8.  Expression and function of ErbB receptors and ligands in the pituitary.

Authors:  Odelia Cooper; George Vlotides; Hidenori Fukuoka; Mark I Greene; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2011-10-27       Impact factor: 5.678

9.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

10.  Invasive adenoma and pituitary carcinoma: a SEER database analysis.

Authors:  Tara M Hansen; Sachin Batra; Michael Lim; Gary L Gallia; Peter C Burger; Roberto Salvatori; Gary Wand; Alfredo Quinones-Hinojosa; Lawrence Kleinberg; Kristin J Redmond
Journal:  Neurosurg Rev       Date:  2014-02-14       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.